share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

SEC announcement ·  May 3 16:29
Summary by Moomoo AI
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more